Investors are closely watching Eli Lilly & Company (LLY) as the pharmaceutical giant prepares to release its fiscal third-quarter results later this week. Experts are expecting strong results driven by the continued success of Lilly's blockbuster medications, particularly its insulin portfolio. However, there are also concerns about potential press